Stockscreener 앱 받기
16.79
3.89%
-0.68
시간 외 거래:
16.95
0.16
+0.95%
전일 마감가:
$17.47
열려 있는:
$17.53
하루 거래량:
1.12M
Relative Volume:
1.13
시가총액:
$1.24B
수익:
$193.35M
순이익/손실:
$-177.58M
주가수익비율:
-6.8531
EPS:
-2.45
순현금흐름:
$-172.43M
1주 성능:
-8.70%
1개월 성능:
-6.41%
6개월 성능:
-20.99%
1년 성능:
-10.17%
1일 변동 폭
$16.61
$17.53
1주일 범위
$16.61
$18.72
52주 변동 폭
$15.99
$28.47
슈뢰딩거 Stock (SDGR) Company Profile
명칭
Schrodinger Inc
전화
503-299-1150
주소
1540 BROADWAY, NEW YORK, NY
SDGR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
16.79 | 1.29B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
222.21 | 35.99B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
70.33 | 12.26B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
41.26 | 7.73B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
85.37 | 7.43B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
39.20 | 7.14B | 11.99B | 24.18M | 234.31M | 0.2956 |
슈뢰딩거 Stock (SDGR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Neutral |
| 2025-08-15 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-08-14 | 개시 | Barclays | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-07-02 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | 재개 | Piper Sandler | Overweight |
| 2022-12-19 | 개시 | Goldman | Neutral |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-13 | 개시 | Berenberg | Buy |
| 2021-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | 개시 | Craig Hallum | Buy |
| 2020-11-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-10-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-02 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-02 | 개시 | Jefferies | Hold |
| 2020-03-02 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
슈뢰딩거 주식(SDGR)의 최신 뉴스
Schrodinger (NASDAQ:SDGR) Shares Down 5.2%Time to Sell? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $91.37 Million Stock Holdings in Schrodinger, Inc. $SDGR - MarketBeat
(SDGR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Schrödinger Inc. stock could be next big winnerMarket Performance Report & Low Risk Entry Point Guides - Bộ Nội Vụ
Schrodinger stock rating reiterated at Buy by TD Cowen on strategic priorities By Investing.com - Investing.com South Africa
Assessing Schrödinger (SDGR) Valuation After Recent Uneven Share Price Momentum - Yahoo Finance
Schrödinger partners with Lilly TuneLab on AI drug discovery - Drug Target Review
Schrodinger stock rating reiterated at Buy by TD Cowen on strategic priorities - Investing.com Nigeria
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities - BioSpace
Schrödinger outlines 2026 priorities after strong 2025 By Investing.com - Investing.com Nigeria
Schrödinger outlines 2026 priorities after strong 2025 - Investing.com
Manas AI Secures Strategic Advantage through Unique Deep Integration with Schrödinger’s Physics + AI Discovery Platform - 01net
Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Chemoinformatics Market to Reach US$ 24.43 Billion by 2033 | CAGR - openPR.com
Schrodinger to offer Eli Lilly’s AI drug discovery platform on its software - WKZO
Will Schrödinger Inc. stock benefit from automation2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда
Schrodinger (NASDAQ:SDGR) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Schrödinger partners with Lilly TuneLab to enhance drug discovery By Investing.com - Investing.com Nigeria
Schrödinger, Inc.'s (NASDAQ:SDGR) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR? - simplywall.st
Schrödinger (SDGR) Partners with Eli Lilly for AI-Driven Drug Di - GuruFocus
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign - 01net
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software - Reuters
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery - MSN
Schrödinger (SDGR) Partners with Eli Lilly for AI Drug Discovery - GuruFocus
Eli Lilly in pact with Schrödinger in AI-related drug discovery - Seeking Alpha
Schrödinger partners with Lilly TuneLab to enhance drug discovery - Investing.com
Schrodinger (NASDAQ:SDGR) Upgraded to "Hold" at UBS Group - MarketBeat
Will Schrödinger Inc. stock recover faster than peersWeekly Trend Recap & Risk Managed Investment Signals - Улправда
Will Schrödinger Inc. stock beat EPS estimatesWeekly Trading Summary & Real-Time Price Movement Reports - Улправда
Is Schrödinger Inc. stock gaining market shareEarnings Recap Report & Reliable Volume Spike Alerts - Улправда
Whale Trades: Will Schrödinger Inc. stock benefit from automationQuarterly Profit Report & Accurate Buy Signal Alerts - Улправда
Schrodinger (SDGR): TD Cowen Maintains Buy Rating, Lowers Price Target | SDGR Stock News - GuruFocus
Schrodinger (NASDAQ:SDGR) Price Target Lowered to $24.00 at TD Cowen - MarketBeat
Why Schrödinger Inc. stock is rated strong buyJuly 2025 Update & Free Real-Time Volume Trigger Notifications - ulpravda.ru
KeyBanc Maintains Overweight Rating for SDGR but Lowers Price Ta - GuruFocus
KeyCorp Issues Pessimistic Forecast for Schrodinger (NASDAQ:SDGR) Stock Price - MarketBeat
KeyBanc Maintains Schrodinger(SDGR.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛
UBS Initiates Coverage of Schrödinger (SDGR) with Neutral Recommendation - Nasdaq
SDGR: UBS Initiates Coverage with Neutral Rating | SDGR Stock Ne - GuruFocus
Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade - Eastern Progress
Schrodinger stock initiated with Neutral rating at UBS on growth concerns - Investing.com Australia
Schrodinger stock initiated with Neutral rating at UBS on growth concerns By Investing.com - Investing.com South Africa
Schrodinger, Inc. (SDGR) Stock Analysis: Unveiling a 47% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Materials Informatics Market Size to Hit USD 736.71 Million by 2035 - GlobeNewswire Inc.
Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now - MSN
Do Options Traders Know Something About Schrodinger Stock We Don't? - MSN
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform - The Globe and Mail
Schrödinger (SDGR) Valuation Check After Analyst Upgrades Back Its Software-Focused Strategic Pivot - Yahoo Finance
Schrödinger (SDGR) Is Up 6.5% After Refocusing On Core Software Business And Analyst UpgradesHas The Bull Case Changed? - Yahoo Finance
Schrödinger (SDGR) Is Up 6.5% After Refocusing On Core Software Platform Over Drug DevelopmentWhat's Changed - simplywall.st
슈뢰딩거 (SDGR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.21%
2.88%
자본화:
|
볼륨(24시간):